CSIR-SA-001-J3
CSIRi001-B
General
Cell Line |
|
| hPSCreg name | CSIRi001-B |
| Cite as: | CSIRi001-B (RRID:CVCL_E3U0) |
| Alternative name(s) |
CSIR-SA-001-J3
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines | No similar lines found. |
| Last update | 8th August 2024 |
| Notes | Line derived from non-diseased donor of self-reported Black African ancestry in South Africa (Ethnolinguistic population group: Zulu) |
| User feedback | |
Provider |
|
| Generator | Council for Scientific and Industrial Research South Africa (CSIR) |
| Distributors | |
| Derivation country | South Africa |
External Databases |
|
| BioSamples | SAMEA115883344 |
| Cellosaurus | CVCL_E3U0 |
General Information |
|
| Publications | |
| * Is the cell line readily obtainable for third parties? |
No |
Donor Information
General Donor Information |
|
| Sex | female |
| Ethnicity | Line derived from non-diseased donor of self-reported Black African ancestry in South Africa (Ethnolinguistic population group: Zulu) |
Phenotype and Disease related information (Donor) |
|
| Diseases | No disease was diagnosed.
|
| Is the medical history available upon request? | No |
| Is clinical information available? | No |
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
Donor Relations |
|
| Other cell lines of this donor | |
External Databases (Donor) |
|
| BioSamples | SAMEA115863934 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | anonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| Does consent expressly prevent the derivation of pluripotent stem cells? | No |
| Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? | No |
| Does consent expressly prevent development of commercial products? | No |
| Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? | No |
| Does consent expressly permit storage of donated embryo/tissue for an unlimited time? | Yes |
| Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
Does consent permit research by | |
| an academic institution? | Yes |
| a public organisation? | Yes |
| a non-profit company? | Yes |
| a for-profit corporation? | Yes |
| How may genetic information associated with the cell line be accessed? | No information |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | CSIR REC |
| Approval number | REC 17_2013 |
| Is there an MTA available for the cell line? | No |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | |
hIPSC Derivation
General |
|
| Source cell type |
Synonyms
|
| Source cell origin |
The dorsal area between the base of the neck and the sacrum.
Synonyms
|
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Sendai virus |
| Is reprogramming vector detectable? |
No |
| Methods used |
RT-PCR
|
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions
| Medium |
Essential 8™
|
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| POU5F1 (OCT-4) |
Yes |
|
||||
| NANOG |
Yes |
|
||||
| SOX2 |
Yes |
|
Microbiology / Virus Screening |
|
| Mycoplasma | Negative |
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
47, XX, seq(20)x3
Passage number: 21
Karyotyping method:
Molecular karyotype (NGS)
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.